Financials Rani Therapeutics Holdings, Inc.
Equities
RANI
US7530181004
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.31 USD | -6.93% | -11.75% | +90.06% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 322.3 | 145.8 | 85.92 | 165.9 | - | - |
Enterprise Value (EV) 1 | 322.3 | 77.02 | 85.92 | 165.8 | 215.9 | 274.7 |
P/E ratio | -38 x | -4.61 x | -2.5 x | -6.35 x | -8.28 x | -8.89 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 119 x | - | - | - | - | 14.5 x |
EV / Revenue | 119 x | - | - | - | - | 24 x |
EV / EBITDA | -6.31 x | -1.22 x | -1.32 x | -2.83 x | -3.41 x | -6.44 x |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | 7.91 x | - | - | - | - |
Nbr of stocks (in thousands) | 19,712 | 24,720 | 25,880 | 26,299 | - | - |
Reference price 2 | 16.35 | 5.900 | 3.320 | 6.310 | 6.310 | 6.310 |
Announcement Date | 31/03/22 | 22/03/23 | 20/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | 2.717 | - | - | - | - | 11.44 |
EBITDA 1 | - | -51.1 | -62.9 | -65.28 | -58.66 | -63.29 | -42.64 |
EBIT 1 | - | -51.6 | -63.45 | -66.1 | -54.17 | -57.79 | -55 |
Operating Margin | - | -1,899.12% | - | - | - | - | -480.79% |
Earnings before Tax (EBT) 1 | - | -53.05 | -63.27 | -67.88 | -54.85 | -59.41 | -62.53 |
Net income 1 | -16.7 | -8.331 | -30.59 | -33.97 | -29.32 | -30.51 | -31.2 |
Net margin | - | -306.62% | - | - | - | - | -272.71% |
EPS 2 | -0.3600 | -0.4300 | -1.280 | -1.330 | -0.9940 | -0.7625 | -0.7100 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 27/04/21 | 31/03/22 | 22/03/23 | 20/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | -13.25 | -13.67 | -15.72 | -16.2 | -17.31 | -16.33 | -18.1 | -17.64 | -13.21 | -13.79 | -14.8 | -14.99 | -14.84 | - | - |
EBIT 1 | -13.36 | -13.78 | -15.85 | -16.34 | -17.48 | -16.52 | -18.29 | -17.86 | -13.43 | -14.03 | -13.72 | -13.85 | -13.76 | -7.25 | -17.5 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -13.34 | -13.76 | -15.81 | -16.32 | -17.38 | -16.83 | -18.66 | -18.33 | -14.06 | -14.78 | -13.63 | -14.06 | -13.78 | -7.995 | -18.24 |
Net income 1 | -5.189 | -6.223 | -7.624 | -7.955 | -8.786 | -8.372 | -9.303 | -9.197 | -7.098 | -7.483 | -7.1 | -7.225 | -7.337 | -0.699 | -10.95 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.2700 | -0.2900 | -0.3100 | -0.3300 | -0.3500 | -0.3300 | -0.3700 | -0.3600 | -0.2700 | -0.2900 | -0.2467 | -0.2400 | -0.2067 | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 31/03/22 | 11/05/22 | 10/08/22 | 10/11/22 | 22/03/23 | 10/05/23 | 11/08/23 | 08/11/23 | 20/03/24 | 06/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | 50 | 109 |
Net Cash position 1 | - | - | 68.8 | - | 0.12 | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | -0.7901 x | -2.55 x |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | -72.6% | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | 0.7500 | - | - | - | - |
Cash Flow per Share | - | -1.650 | -1.950 | - | - | - | - |
Capex | - | 0.51 | 1.62 | - | - | - | - |
Capex / Sales | - | 18.62% | - | - | - | - | - |
Announcement Date | 27/04/21 | 31/03/22 | 22/03/23 | 20/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+90.06% | 166M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- RANI Stock
- Financials Rani Therapeutics Holdings, Inc.